When it comes to payment for performance (P4P), it’s notoriously difficult to know exactly what payers want to see. Useful face-to-face payer discussions about P4P requirements are few and far between — but you don’t want to develop a complex proposal, only to discover that no one is interested.
This report solves the problem by revealing what multiple senior level payers and former payers in the U.S. and Europe are now saying about P4P — and what they are most concerned about.
In Q3 2018, we conducted in-depth interviews with 7 current or former payers in the U.S. and Europe. They told us exactly what they want to see from P4P contracts.
- Where to focus: Not every drug or disease area is suited to P4P. Where do payers believe attention should be focused and why? What areas should pharma avoid?
- Getting payers on side: Introducing P4P adds complexity for everyone. What will persuade payers to make the change and shift away from traditional discounts?
- Sharing the burden: What is fair and reasonable regarding risk sharing? How can cost issues be resolved and ensure both sides view the contract as fair?
- Defining outcomes: What do payers believe is convincing and measurable? How should data be collected and reported — and by whom? What legal constraints must all parties be aware of?
- Valuable guidance: From outcomes to evidence, from suitability to contract length: this report is packed with new strategies to consider and the pitfalls to avoid.